Thread by @ManniMD1

I thoroughly recommend this podcast- an excellent overview on MRD in myeloma, regardless of your views on surrogacy.

Great job educating- @rajshekharucms @End_myeloma @AshKishtagari @BloodCancerTalk

#mmsm

tinyurl.com/y3b63nme

2 pearls that were shared by Dr Costa in 🧵

⭐️Trials that enrolled at time of transplant (as opposed to time of diagnosis) such as STAMINA may not be able to enroll those with the most aggressive disease who relapse during induction or die from toxicity during induction.

⭐️ There were indeed patients who progressed on the MASTER trial after receiving DKRD>transplant while being off therapy.

Yet, even in GRIFFIN (DRVD>Auto>DR) some patients progressed while on doublet maintenance.

We cant attribute progression to them not being on treatment.

^ This brilliant point shows that doublet maintenance isnt enough to adequately treat the highest risk, and better strategies are needed.

Makes me seriously question doublet maintenance strategy :(

Many other pearls- but youll have to listen to it.

I appreciated the nuance with with the surrogacy question was approached!

Thanks all!
(END)